Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

James Noble becomes full-time CEO of Adaptimmune

This article was originally published in Scrip

Executive Summary

Adaptimmune, a biotechnology company focused on the use of engineered T cells to treat cancer, has named James Noble full-time CEO – effective 31 March 2014. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director. Meanwhile, Dr Jonathan Knowles, currently executive chair of both Adaptimmune and Immunocore, will serve as acting CEO of Immunocore until the company's board appoints a permanent replacement. The move comes as both companies are "at the stage where they each require a full-time CEO to lead further development," said Adaptimmune.

Topics

Related Companies

UsernamePublicRestriction

Register

SC024875

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel